Next-Generation Adenovirus Vector-Based Vaccines and Immunotherapies
Legal Citation
Summary of the Inventive Concept
A next-generation vaccine and immunotherapy platform leveraging adenovirus vectors derived from chimpanzee adenovirus AdY25, incorporating advanced delivery systems, checkpoint inhibitors, cytokine expression, and personalized design to enhance immune response and combat infectious diseases.
Background and Problem Solved
The original patent disclosed adenovirus vectors derived from chimpanzee adenovirus AdY25 for vaccine development. However, these vectors had limitations in terms of delivery, immune response, and customization. The new inventive concept addresses these limitations by introducing nanoparticle-based delivery systems, checkpoint inhibitors, cytokine expression, and personalized design to create more effective and targeted vaccines and immunotherapies.
Detailed Description of the Inventive Concept
The new inventive concept comprises four key components: (1) nanoparticle-based delivery systems for targeted administration of adenovirus vectors to specific immune cell types; (2) engineering of adenovirus vectors to express checkpoint inhibitors to enhance immune response; (3) incorporation of cytokine expression in adenovirus vectors for selective expression in antigen-presenting cells; and (4) a platform for personalized vaccine development utilizing machine learning algorithms and a database of adenovirus vectors. These components enable the creation of next-generation vaccines and immunotherapies with improved efficacy, safety, and customization capabilities.
Novelty and Inventive Step
The new claims introduce several novel and non-obvious features, including the use of nanoparticle-based delivery systems, checkpoint inhibitors, cytokine expression, and personalized design, which significantly enhance the functionality and effectiveness of adenovirus vector-based vaccines and immunotherapies. These features overcome the limitations of the original patent and provide a paradigm shift in the field of vaccine development and immunotherapy.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different nanoparticle materials, checkpoint inhibitors, or cytokines. Additionally, the platform for personalized vaccine development could be adapted for use with other types of vectors or immunotherapies. These variations would ensure broad conceptual coverage and flexibility in the development of next-generation vaccines and immunotherapies.
Potential Commercial Applications and Market
The next-generation vaccine and immunotherapy platform has significant commercial potential in the fields of infectious disease prevention and treatment, cancer immunotherapy, and personalized medicine. The target markets include pharmaceutical and biotechnology companies, research institutions, and healthcare organizations. The platform's ability to enhance immune response, reduce side effects, and provide customized solutions could lead to a significant market share and revenue growth.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K48/00 |
| C | C12 | C12N5/0606 |
| C | C12 | C12N7/00 |
| C | C12 | C12N15/86 |
| C | C12 | C12N2710/10021 |
| C | C12 | C12N2710/10042 |
| C | C12 | C12N2710/10044 |
| C | C12 | C12N2800/204 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Molecular virology, vaccine development, and genetic engineering of viral vectors, with expertise in adenovirus vector design, immunology, and gene delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in molecular biology or bioengineering, experienced in viral vector manipulation, immunological techniques, and understanding of gene expression systems, familiar with state-of-the-art vaccine development strategies
Obviousness Rationale
A person skilled in the art would recognize that the PTD's disclosed variations represent predictable extensions of the source patent's core adenovirus vector technology, utilizing standard molecular biology techniques to enhance vector performance and targeting. The proposed modifications align with known strategies for improving viral vector efficacy, such as targeted delivery, immune modulation, and personalized design approaches. These variations would be considered routine optimization within the established framework of adenovirus vector engineering.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,640 |
|---|---|
| Title | Simian adenovirus and hybrid adenoviral vectors |
| Assignee(s) | OXFORD UNIVERSITY INNOVATION LIMITED |